TNYA•benzinga•March 24, 2025 at 12:33 PM

Tenaya Announces Preclinical Data For TN-201 Gene Therapy In Nature Communications: MYBPC3 Gene Replacement Shows Dose-Dependent MyBP-C Protein Increase, Reverses Left Ventricular Hypertrophy; TN-201 In Phase 1b/2 Trial For MYBPC3-Associated Hypertrophic

No summary available.

Read the full article from the original source for complete details and context.

Article published on March 24, 2025 by benzinga